PolyTherics has extended its ThioBridge antibody-drug conjugate (ADC) collaboration with MacroGenics. Financial terms of the amended agreement were not disclosed.
PolyTherics developed ThioBridge for site-specific conjugation of cytotoxic payloads to antibodies to provide more stable and less heterogeneous ADCs. MacroGenics has two antibody technology platforms: its DART (Dual-Affinity Re-Targeting) bi-specific platform, in which a single recombinant molecule is able to target two different antigens; and fragment crystallisable region-optimised antibodies with improved effector function.
The PloyTherics-MacroGenics collaboration was extended following the successful outcome of a research programme undertaken in 2013 under a research collaboration and option agreement, in which ThioBridge was used to conjugate a cytotoxic payload to a range of DART antibodies. MacroGenics and PolyTherics will collaborate in the application of its ThioBridge technology to a number of product candidates derived from MacroGenics' antibody platforms. MacroGenics has an option to licence the ThioBridge technology for the development of these product candidates and PolyTherics would receive development milestones and a single-digit percentage royalty on sales of any ThioBridge ADC derived from this collaboration.